Skip to content

Research Areas

Biosfer Teslab has more than 90 publications in multiple research areas. 

Abstract  Renal complications are the major cause of morbidity and mortality in patients with familial lecithin-cholesterol acyltransferase (LCAT) deficiency (FLD). We report …

Abstract  Gut microbiota has been suggested to affect lipid metabolism. The objective of this study was to characterize the faecal microbiota signature …

Abstract The assessment and prevention of cardiovascular risk (CVR) that persists in patients with dyslipidaemia despite treatment and achievement of goals specific …

Abstract  The polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women in reproductive age. Obesity and low-grade chronic inflammation are …

This study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of …

Abstract  Lipid profiling, which includes fatty acids, phospholipids, glycerides, and cholesterols is extremely important because of the essential role lipids play in …

Abstract Background: There is growing evidence that oxidative stress (OS) is a critical factor linking obesity with its associated comorbidities, such as cardiovascular …

Abstract  Objective: To investigate the metabolic and immunologic factors associated with the presence of central arterial stiffness as measured by the augmentation …

Abstract  While cholesterol content in high-density lipoproteins (HDLs) is a well-established inverse marker of cardiovascular risk, the importance of HDL-triglyceride (HDL-TG) concentration …

Abstract Acute-phase glycoprotein 1H-NMR spectroscopy profiles serve as surrogate markers of chronic inflammation in metabolic disorders such as obesity, diabetes and polycystic ovary …

ACCIÓ GRANT

BIOSFER TESLAB, SL with the support of ACTION in the frame of the Operative Program FEDER Catalonia 2014-2020 has carried out the “DEVELOPMENT And VALIDATION OF ADVANCED DIAGNOSTIC TEST Of INFLAMMATION And  INSULIN RESISTANCE FOR THE IMPROVEMENT OF  CARDIOVASCULAR RISK USING NUCLEAR MAGNETIC RESONANCE”  (RD15-1-0013).

Biosfer Teslab, along the project, has developed a system of prediction, using of advanced prediction tests, with the aim to improve the evaluation of cardiovascular risk and to identify those individuals with residual cardiovascular risk that would remain undiagnosed with classical risk factors.

In particular, the company has developed a glycoprotein test and a LMWM test - that includes, branched amino acids -, as they have been identified as inflammatory markers and involved in insulin resistance processes, respectively.

The Agency for the Competitiveness of the Company, ACTION, aiding to industrial research centers and experimental development, has granted Biosfer Teslab with an amount of 67,728.97 €.

This aid is programmed in the axis 1, "Boost research, technological development and innovation", specific objective OE 1.2.2, "Transfer and spreading of technology and cooperation between companies and universities or other research centers", line of action "Collaborative R+D projects" under the framework of the FEDER Operational Program of Catalonia 2014-2020